The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration

Date: January 22, 2010
Pages: 151
US$ 4,795.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: F18A0C484F1EN

Download PDF Leaflet

The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
Nutrigenomics explores how nutrients or bioactive dietary compounds can influence gene expression and an individuals risk to certain diseases. Nutrigenetics is the study of how variations in an individual’s genetic makeup can increase or decrease the need for a specific nutrient or bioactive food component.

Nutrigenomics has the potential to impact various parts of the food chain including the genetic modification of crops and animal feeds, the development of nutrigenomic tests to monitor food safety and personalization of diets, as well as the identification of nutritional supplements and nutrigenomic based products which may offer potential health benefits.

The consumer environment is driving growth in the Nutrition & Health market. Over the past decade, consumers have become more concerned for their health and are increasingly inclined to invest in DTC nutrigenetic tests to assess their risk of disease and obtain dietary advice. Healthcare providers too, are keen to shift some of the burden of healthcare costs to individuals and recognize that the personalization of nutrition may be beneficial. The Health and nutrition market is currently worth around $485 billion.

This report reviews the business strategies of leading companies regarding the adoption of nutrigenomic technologies and establishment of public-private partnerships as well as potential opportunities for biomarker discovery with the pharma and diagnostic industry to personalize nutrition and medicine.

Key features of this report

  • Identify leading academic groups and companies at the forefront of the nutrigenomic research who will drive the market towards a more personalized approach to nutrition and disease prevention.
  • Assess the nutrigenomic testing market, leading companies and its role in empowering consumers to take a more active role in making dietary decisions and maintaining their health status
  • Review the backgrounds, strategies and business models of companies and assess potential opportunities to collaborate with the pharma and diagnostic industry.

  • Scope of this report

  • Identify the companies leading the field in nutrigenomic research from ingredient & food manufacturers to nutrigenomic testing companies
  • Review their key products and business alliances which enable them to participate in this evolving field of science
  • Identify points of convergence of the pharma, diagnostic and food and drinks markets which may offer new opportunities for co development
  • Review market drivers regarding the adoption of nutrigenomic information and the personalization of nutrition.

  • Key Market Issues

  • The food market is changing: Over the past decade, consumers have become more concerned for their health and wellbeing. The roll of the food and drinks industry is changing and shifting towards a more benefit driven and preventative approach. In order to respond to market dynamics the companies have needed to adopt an “open network” model to gain access to innovative research and technologies which will drive future product development.
  • Nutrigenomics & pharmacogenomics are related in their approach to identify subpopulations that respond to treatment/nutrition. The application of these technologies may lead to the identification of old and new ingredients that have beneficial effects for specific consumer groups, helping to maintain health and wellness and leading to the personalization of treatment and diets. The scientific evidence is mounting however, large scale clinical studies are needed to reinforce data which can be utilized initially in dietary guidance and latterly to support health claims.
  • Nutrigenomic testing marketing is growing and has been fueled by consumer concerns for their health and the demand for genomic information. Increasingly,consumers are inclined to invest in DTC nutrigenomic tests to assess their health status and obtain dietary guidance. This market is currently estimated to be worth US$730 million and growing by 20% per annum.

  • Key findings from this report

  • The food and drinks industry has been undergoing major regulatory changes during the last few years, particularly with respect to health and dietary claims. Added to this, the adoption and application of nutrigenomic technologies, may provide additional clinical data to substantiate claims and provide new opportunities to develop products which target consumer sub groups. This may require further adjustments in the regulatory framework to stimulate innovation but ensure consumer safety.
  • There are significant market opportunities for the development of nutrigenomic tests and products which target consumer groups. Successful products will need to be supported by robust and reproducible clinical studies - these will cost time and money and will only be feasible through public / private collaborations. The results will enable the manufacturer to clearly differentiate themselves and target specific groups – leading to fragmentation of the market and a shift in he healthcare paradigm from treatment towards prevention.
  • Synergies exist between the food and drinks industry and the pharma and diagnostic industry that may create opportunities (e.g. biomarker discover) but also lead to conflicts as the food manufacturers aim to keep consumers healthier for longer forcing pharma to switch to a more preventative strategy by targeting lifestyle disease (e.g. obesity) as their pool of unhealthy ill patients contracts.

  • Key questions answered

  • Which companies are involved in nutrigenomic testing and how may they influence the uptake of personalised nutrition?
  • How are Health and Nutrition market leaders applying nutrigenomic research in their R&D programs to develop new products or create new marketing opportunities?
  • What potential opportunities exist between the food and drinks industry and the pharma and diagnostic industry to co-develop biomarkers for the development of personalised nutrition and medicine.

  • The Future of Nutrigenomics
    Executive summary 10
    Defining nutrigenomics 10
    Market drivers 11
    Collaborative nutrigenomic research & consortia 12
    Leading food & drinks companies: nutrigenomic strategies 13
    Leading nutrigenomic testing companies 14
    Opportunities: convergence of pharma & diagnostics 15
    Challenges: regulation, ethical & IP issues 16
    Conclusions 17


    Summary 20
    Introduction 21
    ‘Omic technologies 23
    Nutrigenomics and the food & drinks industry 26
    Nutrigenomics & food products 28
    Nutrigenomics & personalized nutrition 28
    Report outline 29


    Summary 32
    Introduction 33
    Drivers for personalized nutrition 34
    Healthy aging 34
    Consumer demographics 36
    Chronic non-communicable disease 38
    Urbanization and the emerging markets 40
    Global health economics 41
    Conclusions on drivers for personalized nutrition 42


    Summary 46
    Introduction 47
    Nutrigenomic research consortia 47
    Nutrigenomic research in the EU 49
    The European Nutrigenomics Organization (NuGO) 49
    DiOGenes 51
    TI Food and Nutrition 51
    Vision EpiFood Project 53
    Canada Foundation for Innovation (CFI) 53
    Public-private in age-related diseases 53
    Nutrigenomic research in the US 55
    Public-private partnership: genetically modified crops 57
    Nutrigenomic research across the world 58
    International Society of Nutrigenetics/Nutrigenomics (ISNN) 58
    Conclusions 59


    Summary 62
    Introduction 63
    Ingredients manufacturers approach to nutrigenomics 64
    BASF 64
    Chr Hansen 66
    DSM 69
    Food manufacturers’ approach to nutrigenomics 73
    Group Danone 73
    Nestlé 76
    Unilever 78
    Pharma industry M&A in consumer nutrition 80
    The evolving open network model 82
    Co-development opportunities 86
    Areas for market growth & time scales 88
    Conclusions 90


    Summary 94
    Introduction 95
    Market leaders 95 97
    GeneLink 98
    Gene Smart 98
    Genova Diagnostics 99
    Interleukin Genetics Inc 100
    WellGen Inc. 102
    Conclusions 104


    Summary 108
    Introduction 109
    Nutrigenomics vs pharmacogenomics 110
    Global health issues treatment vs prevention 115
    Convergence of the pharmaceutical & diagnostic market 116
    Conclusions 118


    Summary 120
    Introduction 121
    Regulation of nutrigenomic foods 122
    Europe 123
    Japan 124
    Regulation of nutrigenomic tests 125
    Ethical issues 127
    Public awareness & perceptions 128
    Intellectual Property 129
    Conclusions 131


    Summary 134
    The food & drinks market 135
    Global genetic testing market 136
    Market trends 136
    Overall conclusions 137
    Appendix 140
    Primary research methodology 140
    Acknowledgments 141
    Glossary 142
    Index 145
    Bibliography 148
    Endnotes 151


    Figure 1.1: Nutrigenetics and nutrigenomics 22
    Figure 1.2: The ‘omics technologies 24
    Figure 1.3: The functional genomic tool box 26
    Figure 1.4: Applications of nutrigenomics in the food chain 27
    Figure 2.5: Drivers for the food & drinks industry 33
    Figure 2.6: The ageing population a driver for personalized nutrition 35
    Figure 2.7: Personalized nutrition targeting consumer segments 36
    Figure 2.8: Population over 60: world and developed regions (1950-2050) 37
    Figure 2.9: Nutritional challenges – obesity & metabolic syndrome 38
    Figure 2.10: Growth in consumers in developing & emerging countries (2008-2018) 40
    Figure 2.11: Healthcare expenditure as a share of GDP (2006) 41
    Figure 2.12: Target population of nutrigenomic based products 43
    Figure 4.13: BASF approach to gene discovery 65
    Figure 4.14: DSMs sales growth targeting four emerging business areas 70
    Figure 4.15 DSMs R&D competencies 72
    Figure 4.16 An International and interdisciplinary network 75
    Figure 4.17 Diversify & de-risk through externalization 84
    Figure 4.18 Open network model 85
    Figure 4.19: Waves of nutrigenomic development 90
    Figure 5.20: WellGen’s nutrigenomic based discovery 103
    Figure 6.21: Nutrigenomics vs pharmacogenomics 111
    Figure 6.22: Relationship of drugs, disease, genes and gene products 113
    Figure 8.23: Health and nutrition market segments (2009) 135
    Figure 8.24: Nutrigenomic impact on personalized nutrition 139


    Table 3.1: European Consortia and Nutrigenomic Research Programs 50
    Table 3.2: Nutrigenomics Network Programs 55
    Table 4.3: Stakeholders in nutrigenomic research and personalized nutrition 63
    Table 4.4: Chr Hansen - strategic alliances & investments 67
    Table 4.5: Nestlé nutrigenomic alliances & investments 77
    Table 4.6: Divestment of Animal, Consumer & Medical Nutrition Divisions 80
    Table 4.7: Consumer Health Divisions of Pharmaceutical Companies 81
    Table 4.8: Alliance between Food, Pharma, Biotech and the Diagnostic Industries 82
    Table 5.9: Categorization of genetic variations that may be included in nutrigenomic tests 96
    Table 5.10: Categorization of genetic variations that may be included in nutrigenomic tests 97
    Table 6.11: Known diet- gene interactions 112
    Table 6.12: Known gene-nutrient interactions 114

    Skip to top

    Ask Your Question

    The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
    Company name*:
    Contact person*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: